Suncoast Equity Management Makes New $421,000 Investment in TuHURA Biosciences (NASDAQ:HURA)

Suncoast Equity Management purchased a new stake in shares of TuHURA Biosciences (NASDAQ:HURA) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 102,997 shares of the company’s stock, valued at approximately $421,000.

Separately, Apollon Wealth Management LLC acquired a new stake in shares of TuHURA Biosciences during the fourth quarter worth about $253,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Trading Up 3.8 %

Shares of HURA opened at $3.30 on Friday. TuHURA Biosciences has a 52 week low of $2.84 and a 52 week high of $14.60. The business has a 50-day moving average of $4.41.

Analysts Set New Price Targets

Several brokerages recently weighed in on HURA. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Maxim Group initiated coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.